Dear Editor,

Recently, the paper by Wang et al. demonstrated a significant relationship between cerebrovascular disease and patients with severe coronavirus disease 2019 (COVID-19) (OR = 3.89, 95% CI: 1.64--9.22, *P* = 0.002) in a meta-analysis based on three published studies \[[@CR1]\]. To our knowledge, there have been several published articles reporting the association between cerebrovascular disease and the risk of mortality in COVID-19 patients \[[@CR2]--[@CR6]\]. However, the conclusions are not consistent. Therefore, it is required to clarify the association of the cerebrovascular disease with the risk of mortality in COVID-19 patients by using a systematically quantitative meta-analysis.

Relevant studies were extracted by systematic retrieval of PubMed, Web of Science, and China National Knowledge Infrastructure (CNKI) up to date to April 30, 2020. The searching terms used were as follows: "coronavirus" or "COVID-19" or "SARS-CoV-2" or "2019-nCoV" and "clinical" and "mortality" or "outcome." Duplicate results were removed. All studies were evaluated for eligibility by two independent reviewers (Ying Wang and Li Shi). Inclusion criteria are the following: (1) studies reporting extractable data on a past history of cerebrovascular disease in laboratory-confirmed COVID-19 patients and (2) compared patients between survivors and non-survivors. Exclusion criteria are as follows: (1) reviews and case reports and (2) non-survivor subgroup was not included in the study. Odds ratio (OR) with its 95% confidence intervals (CI) was applied to estimate the combined effects. Heterogeneity was evaluated with the *I*^2^ test. A fixed-effects model was selected to compute the combined effects if there was no obvious heterogeneity among studies (*I*^2^ ≤ 50%). Otherwise, a random-effects model was applied \[[@CR7]\]. The possibility of publication bias was checked by using Egger's test and Begg's test \[[@CR8]\]. Sensitivity analysis was carried out by excluding studies successively \[[@CR9]\]. The statistical analysis was carried out using the Stata 11.2 (StataCorp, College Station, TX), and the *P* value \< 0.05 was considered to be statistically significant.

We found a total of 966 records, and 741 remained after the removal of duplicates. Forty-two records remained after reading the title and abstract. After reading the full text, we excluded 34 studies that did not report a past history of cerebrovascular disease and finally included eight articles for our meta-analysis. Included studies grouped into survival and non-survival groups (six articles), recovered and non-survival groups (one article), and discharged and non-survival groups (one article). The essential characteristics are presented in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of the included studiesAuthorsLocationGroupSamplesNon-survival patientsSurvival patientsAgeMaleCerebrovascular/nAgeMaleCerebrovascular/nYang Xiaobo et al. (PMID: 32105632)ChinaSurvival vs. non-survival5264.6 (11.2)21 (66%)7/3251.9 (12.9)14 (70%)0/20Cao Jianlei et al. (PMID: 32239127)ChinaSurvival vs. non-survival10272 (63--81)13 (76%)3/1753 (47--66)40 (47%)3/85Ruan Qiurong et al. (PMID: 32253449)ChinaDischarged vs. non-survival15067 (15--81)49 (72%)7/6850 (44--81)53 (65%)5/82Li Juyi et al. (PMID: 32324209)ChinaSurvival vs. non-survival36272 (64.5--82)50 (65%)37/7765 (57.5--71)139 (48%)31/285Chen Tao et al. (PMID: 32217556)ChinaRecovered vs. non-survival27468 (62--77)83 (73%)4/11351 (37--66)88 (55%)0/161Wang Lang et al. (PMID: 32240670)ChinaSurvival vs. non-survival33976 (70--83)39 (60%)10/6568 (64--74)127 (46%)11/274Chen Ruchong et al. (PMID: 32304772)ChinaSurvival vs. non-survival195069 (51--86)30 (60%)6/50NRNRNRTomlins Jennifer et al. (PMID: 32353384)UKSurvival vs. non-survival9577 (72--85)12 (60%)2/2074 (56--82)48 (64%)6/75All values are *n* (%), mean (SD), and median (IQR)*NR* not reported

Seven studies compared cerebrovascular disease in non-survival vs. survival patients with a total of 1374 confirmed COVID-19 patients including 392 (28.5%) non-survival cases. A past history of cerebrovascular disease was reported in 126 patients (9.2%), of whom 70 (55.6%) patients were classified as non-survivors. Besides, one study by Chen et al. individually provided a hazard ratio (HR) (HR = 4.28, 95% CI: 1.07--8.94) for cerebrovascular disease and mortality of COVID-19 patients \[[@CR10]\].

Our meta-analysis showed that cerebrovascular disease was significantly associated with an increased risk of mortality in COVID-19 patients on the basis of a fixed-effects model (OR = 4.78, 95% CI: 3.24--7.03, *P* \< 0.001) (Fig. [1a](#Fig1){ref-type="fig"}). Heterogeneity was not observed presently (*I*^2^ = 22.4%, *P* = 0.251). The sensitivity analysis indicated that the combined OR did not change significantly after deleting each study one by one. Although the combined OR was declined (OR = 3.319, 95% CI: 1.98--5.57, *P* \< 0.001) after deleting Li Juyi et al.'s study \[[@CR5]\], the result still indicated that cerebrovascular disease was associated with an increased risk of mortality in COVID-19 patients (Fig. [1b](#Fig1){ref-type="fig"}). Hence, we can consider our result to be robust. The results of Egger's test (*P* = 0.517) (Fig. [1c](#Fig1){ref-type="fig"}) and Begg's test (*P* = 0.711) (Fig. [1d](#Fig1){ref-type="fig"}) indicated there was no publication bias presently.Fig. 1Odds ratio (OR) with its 95% confidence intervals (CI) for cerebrovascular disease (**a**), sensitivity analysis for cerebrovascular disease (**b**), publication bias assessment: Egger's test (**c**) and Begg's test (**d**)

To our knowledge, a previous meta-analysis by Aggarwal et al. did not observe a significant association between a past history of cerebrovascular disease and the risk of mortality in COVID-19 patients based on two published studies (OR = 2.33, 95% CI: 0.77--7.04) \[[@CR11]\]. However, in our present meta-analysis based on eight published studies, the cerebrovascular disease was identified to be significantly associated with an increased risk of mortality in COVID-19 patients. Some patients with COVID-19 have neurological symptoms, such as headache, anosmia, dysgeusia, dizziness, and impaired consciousness \[[@CR12]\]. There is evidence that SARS-CoV-2 has neuro-invasive abilities and might spread from the respiratory system to the central nervous system \[[@CR13], [@CR14]\]. COVID-19 may also predispose cerebrovascular diseases due to inflammation, hypoxia, and diffuse intravascular coagulation \[[@CR15]\]. Thus, clinicians should strengthen the monitoring of COVID-19 patients with the cerebrovascular disease.

This study has several limitations. Firstly, except for one article from the UK, most of the articles came from China. Secondly, some patients had more than one coexisting illness in our included studies. Hence, our conclusion needs to be treated with caution and further analyses including more studies are needed to verify our findings.
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